India's Sun Pharma to buy Organon in $11.75 billion all-cash deal
This story raises questions about governance, accountability, and American values.
Source: Reuters
1 min read
India's Sun Pharmaceutical Industries will buy Organon & Co in an all‐cash deal, valuing the U.S. drugmaker at about $11.75 billion including debt, the companies said on Sunday.
Original source:
Read at ReutersHow We See It
New Republican Times Editorial Board